BRUSSELS |
BRUSSELS (Reuters) – Belgian biotech organisation Ablynx pronounced a clinical investigate of a rheumatoid arthritis drug ALX-0061 showed earnest formula and it was now deliberation how to serve rise a drug, including a partnership understanding with a bigger company.
“We are now questioning a several possibilities by that we can swell a growth of ALX-0061, including discussions with intensity partners and other paths that will concede us to maximize a value of this asset,†Chief Executive Edwin Moses pronounced in a matter on Wednesday.
Ablynx had carried out a investigate on 37 patients over a march of 24 weeks and pronounced a drug was well-tolerated and showed certain results.
(Reporting by Robert-Jan Bartunek; modifying by Philip Blenkinsop)
